Same thing happened to Inovio but if you look at the 6 month, YTD or 1 year Inovio chart (see below), the share price continues on an upward trajectory in spite of the claims with obvious occasional pull backs. If the science is sound, the analysts continue to support a BUY rating for SRNE which they do (avg analyst projected share price is $22.50) and the trials continue to be successful which they are, Sorrento will follow the course of Inovio and begin to climb on an upward trajectory IMO.
Incidentally, the whole Covid pharmaceutical sector is down today. Compared to the 5 companies below, Sorrento is down only 3.23% compared to the others who are down between 4.08% and 9.69%.
Symbol Last Price Change % Change MRNA
Moderna, Inc. 52.12 -5.59 -9.69% CODX
Co-Diagnostics, Inc. 17.30 -0.74 -4.08% INO
Inovio Pharmaceuticals, Inc. 13.13 -1.33 -9.20% NVAX
Novavax, Inc. 44.45 -3.72 -7.72% VXRT
Vaxart, Inc. - Common Stock 2.6200 -0.1600 -5.76
* These are my personal opinions based on available data, please do your own due diligence before trading this or any stock.